« Previous
Next »
Titles
- Cost savings2
- Biologics in perspective: the case for generic biologic drugs1
- Competitive bidding in drug procurement: evidence from China1
- Congreso Internacional de Derecho y Economia Farmaceutica1
- Drug price moderation in Germany: lessons for U.S. reform efforts1
- Equilibrium effects of pharmaceutical bundling: evidence from India1
- Indication-specific pricing of pharmaceuticals in the United States health care system: a report from the 2015 ICER Membership Policy Summit1
- Medicaid's most costly outpatient drugs1
- Medicare Part D1
- Navigating the pharmacy benefits marketplace1
- Prior authorization requirements for proprotein convertase subtilisin/kexin type 9 inhibitors across US private and public payers1
- Snapshots of recent state initiatives in Medicaid prescription drug cost control1
- Survey brief: drug companies reduce patients’ access to care by limiting 340B community pharmacies1
- The effect of Medicare Part D on evergreening, generic entry, and drug prices1
- The role of clinical and cost information in Medicaid pharmacy benefit decisions: experience in seven states1
- What's the latest on Medicare drug price negotiations?1